The publication builds on earlier findings and strengthens the scientific rationale for Arch Biopartners’ CKD platform, which aims to develop novel therapeutics targeting IL-32 in chronic kidney disease.
Background
Diabetic kidney disease (DKD) is a severe complication of diabetes mellitus and the leading cause of chronic kidney disease worldwide. Among the many drivers of tubular injury, lipid accumulation and inflammation are emerging as major contributors to kidney disease progression, but the molecular link between lipid metabolism and inflammatory signaling remains to be determined.
Publication Details
Citation
Meadows, K., Chung, H., Vo, S. et al. Spatial transcriptomics identifies IL-32 as a lipid droplet-associated cytokine linked to tubular injury in human diabetic kidney disease. Inflamm. Res. 75, 33 (2026). https://doi.org/10.1007/s00011-026-02192-y
Authors
Kieran Meadows, Hyunjae Chung, Son Vo, Aysa Imanzadeh, Heewon Seo, Sisay Getie Belay, Asha Swamy, Wulin Teo, Kevin Chapman, Graciela Andonegui, Hallgrimur Benediktsson, Peter K. Stys, Thang Pham, Daniel A. Muruve & Justin Chun.
